What do yall think of editas medicine? $EDIT

Original Reddit post

Author argues Editas Medicine is a beaten-down but real CRISPR company with low expectations and asymmetric upside from any positive data, partnership, or asset sale.

EDIT — LONG The author argues Editas Medicine is a real CRISPR company with actual IP and ongoing eye and liver programs whose stock has been destroyed by dilution, biotech winter, and bad sentiment, leaving expectations near zero. Because the market cap is low, any positive development such as data, a partnership, or an asset sale could cause a hard repricing. The author frames this as high risk/high reward, noting it could bleed for a long time before suddenly moving, and claims a 10x is possible.

but it’s still a real crispr company with actual ip and ongoing programs (eye + liver). market cap is low enough that if literally anything goes right (data, partnership, asset sale, etc) the stock could reprice hard.